Voyager Therapeutics (VYGR) reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer’s disease. Data on ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical muri ...

For example, all statements Voyager makes regarding Voyager’s ability to advance its AAV-based gene therapy programs and tau antibody program, including expectations for Voyager’s achievement ...

March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its ...

KuCoin makes it easier for you to maximize profits and unlock new financial opportunities with the newly launched KCS Loyalty ...

a scientist from the Voyager program. "Every bit of additional data we have gathered since then is not only valuable bonus science for heliophysics, but also a testament to the exemplary ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. An illustration of the Voyager 2 spacecraft exploring space beyond the solar system.

Voyager program scientist at NASA Headquarters in Washington, in a statement. “Every bit of additional data we have gathered since then is not only valuable bonus science for heliophysics ...

Voyager program scientist at NASA Headquarters in Washington. "Every bit of additional data we have gathered since then is not only valuable bonus science for heliophysics, but also a testament to ...